Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Journal of Cataract and Refractive Surgery
|
October 12, 2004
Optical formula to predict outcomes after implantation of accommodating intraocular lenses
Tom Missotten, Thibault Verhamme, Johan Blanckaert, et al.
Acta Ophthalmologica
|
August 28, 2015
Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion
Koen A van Overdam, Tom Missotten, Leigh H Spielberg
Investigative Ophthalmology & Visual Science
|
February 1, 2008
Influence of intraoperative course on visual outcome after an RPE-choroid translocation
Kristel Maaijwee, Tom Missotten, Paul Mulder, et al.
Statistics in Medicine
|
December 21, 2018
A joint model for dynamic prediction in uveitis
Mia Klinten Grand, Koenraad Arndt Vermeer, Tom Missotten, et al.
Ophthalmology
|
December 23, 2006
Acute retinal necrosis features, management, and outcomes
Chun H Lau, Tom Missotten, Joel Salzmann, et al.
Acta Ophthalmologica
|
January 8, 2013
Vision-related quality of life in patients with birdshot chorioretinopathy
Jonas J W Kuiper, Tom Missotten, Seerp G Baarsma, et al.
Acta Ophthalmologica
|
September 30, 2016
Early surgical treatment of retinal hemangioblastomas
Koen A van Overdam, Tom Missotten, Emine Kilic, et al.
Plos One
|
February 23, 2017
SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
Martijn S Visser, Sankha Amarakoon, Tom Missotten, et al.
Molecular Vision
|
April 10, 2007
Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis
Muhammad A Ahad, Tom Missotten, Atiyeh Abdallah, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 16, 2020
Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial
Martijn S Visser, Sankha Amarakoon, Tom Missotten, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Journal of Cataract and Refractive Surgery
|
October 12, 2004
Optical formula to predict outcomes after implantation of accommodating intraocular lenses
Tom Missotten, Thibault Verhamme, Johan Blanckaert, et al.
Acta Ophthalmologica
|
August 28, 2015
Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion
Koen A van Overdam, Tom Missotten, Leigh H Spielberg
Investigative Ophthalmology & Visual Science
|
February 1, 2008
Influence of intraoperative course on visual outcome after an RPE-choroid translocation
Kristel Maaijwee, Tom Missotten, Paul Mulder, et al.
Statistics in Medicine
|
December 21, 2018
A joint model for dynamic prediction in uveitis
Mia Klinten Grand, Koenraad Arndt Vermeer, Tom Missotten, et al.
Ophthalmology
|
December 23, 2006
Acute retinal necrosis features, management, and outcomes
Chun H Lau, Tom Missotten, Joel Salzmann, et al.
Acta Ophthalmologica
|
January 8, 2013
Vision-related quality of life in patients with birdshot chorioretinopathy
Jonas J W Kuiper, Tom Missotten, Seerp G Baarsma, et al.
Acta Ophthalmologica
|
September 30, 2016
Early surgical treatment of retinal hemangioblastomas
Koen A van Overdam, Tom Missotten, Emine Kilic, et al.
Plos One
|
February 23, 2017
SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
Martijn S Visser, Sankha Amarakoon, Tom Missotten, et al.
Molecular Vision
|
April 10, 2007
Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis
Muhammad A Ahad, Tom Missotten, Atiyeh Abdallah, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
July 16, 2020
Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial
Martijn S Visser, Sankha Amarakoon, Tom Missotten, et al.
Page
of 4